Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2020-2026
SKU ID : QYR-15313092 | Publishing Date : 20-Feb-2020 | No. of pages : 92
Detailed TOC of Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder Revenue
1.4 Market Analysis by Type
1.4.1 Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Short-Acting Bronchodilators
1.4.3 Corticosteroids
1.4.4 Methylxanthines
1.4.5 Long-Acting Bronchodilators
1.4.6 Phosphodiesterase-4 Inhibitors
1.4.7 Others
1.5 Market by Application
1.5.1 Global Chronic Obstructive Pulmonary Disorder Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Chronic Obstructive Pulmonary Disorder Market Perspective (2015-2026)
2.2 Chronic Obstructive Pulmonary Disorder Growth Trends by Regions
2.2.1 Chronic Obstructive Pulmonary Disorder Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Obstructive Pulmonary Disorder Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Obstructive Pulmonary Disorder Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Obstructive Pulmonary Disorder Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder Players by Market Size
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder Players by Revenue (2015-2020)
3.1.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Obstructive Pulmonary Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio
3.2.1 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder Revenue in 2019
3.3 Chronic Obstructive Pulmonary Disorder Key Players Head office and Area Served
3.4 Key Players Chronic Obstructive Pulmonary Disorder Product Solution and Service
3.5 Date of Enter into Chronic Obstructive Pulmonary Disorder Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Chronic Obstructive Pulmonary Disorder Historic Market Size by Type (2015-2020)
4.2 Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Type (2021-2026)
5 Chronic Obstructive Pulmonary Disorder Breakdown Data by Application (2015-2026)
5.1 Global Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
5.2 Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
6.2 Chronic Obstructive Pulmonary Disorder Key Players in North America (2019-2020)
6.3 North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
6.4 North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
7.2 Chronic Obstructive Pulmonary Disorder Key Players in Europe (2019-2020)
7.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
7.4 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
8 China
8.1 China Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
8.2 Chronic Obstructive Pulmonary Disorder Key Players in China (2019-2020)
8.3 China Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
8.4 China Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
9.2 Chronic Obstructive Pulmonary Disorder Key Players in Japan (2019-2020)
9.3 Japan Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
9.4 Japan Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
10.2 Chronic Obstructive Pulmonary Disorder Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
11 India
11.1 India Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
11.2 Chronic Obstructive Pulmonary Disorder Key Players in India (2019-2020)
11.3 India Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
11.4 India Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chronic Obstructive Pulmonary Disorder Market Size (2015-2020)
12.2 Chronic Obstructive Pulmonary Disorder Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020)
12.4 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GSK
13.1.1 GSK Company Details
13.1.2 GSK Business Overview and Its Total Revenue
13.1.3 GSK Chronic Obstructive Pulmonary Disorder Introduction
13.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020))
13.1.5 GSK Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview and Its Total Revenue
13.2.3 Pfizer Chronic Obstructive Pulmonary Disorder Introduction
13.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview and Its Total Revenue
13.3.3 Merck Chronic Obstructive Pulmonary Disorder Introduction
13.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.3.5 Merck Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview and Its Total Revenue
13.4.3 Novartis Chronic Obstructive Pulmonary Disorder Introduction
13.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 AstraZeneca
13.5.1 AstraZeneca Company Details
13.5.2 AstraZeneca Business Overview and Its Total Revenue
13.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder Introduction
13.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.5.5 AstraZeneca Recent Development
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Details
13.6.2 Boehringer Ingelheim Business Overview and Its Total Revenue
13.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Introduction
13.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.6.5 Boehringer Ingelheim Recent Development
13.7 Teva Pharmaceuticals
13.7.1 Teva Pharmaceuticals Company Details
13.7.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Introduction
13.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.7.5 Teva Pharmaceuticals Recent Development
13.8 Ario Pharma
13.8.1 Ario Pharma Company Details
13.8.2 Ario Pharma Business Overview and Its Total Revenue
13.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder Introduction
13.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.8.5 Ario Pharma Recent Development
13.9 Roche
13.9.1 Roche Company Details
13.9.2 Roche Business Overview and Its Total Revenue
13.9.3 Roche Chronic Obstructive Pulmonary Disorder Introduction
13.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.9.5 Roche Recent Development
13.10 Ache
13.10.1 Ache Company Details
13.10.2 Ache Business Overview and Its Total Revenue
13.10.3 Ache Chronic Obstructive Pulmonary Disorder Introduction
13.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
13.10.5 Ache Recent Development
13.11 Almirall
10.11.1 Almirall Company Details
10.11.2 Almirall Business Overview and Its Total Revenue
10.11.3 Almirall Chronic Obstructive Pulmonary Disorder Introduction
10.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
10.11.5 Almirall Recent Development
13.12 Aquinox Pharmaceuticals
10.12.1 Aquinox Pharmaceuticals Company Details
10.12.2 Aquinox Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Introduction
10.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
10.12.5 Aquinox Pharmaceuticals Recent Development
13.13 Asmacure
10.13.1 Asmacure Company Details
10.13.2 Asmacure Business Overview and Its Total Revenue
10.13.3 Asmacure Chronic Obstructive Pulmonary Disorder Introduction
10.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
10.13.5 Asmacure Recent Development
13.14 Astellas Pharma
10.14.1 Astellas Pharma Company Details
10.14.2 Astellas Pharma Business Overview and Its Total Revenue
10.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder Introduction
10.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
10.14.5 Astellas Pharma Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Figures, Tables and Charts Available in Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2020-2026
List of TablesTable 1. Chronic Obstructive Pulmonary Disorder Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder Revenue
Table 3. Ranking of Global Top Chronic Obstructive Pulmonary Disorder Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Short-Acting Bronchodilators
Table 6. Key Players of Corticosteroids
Table 7. Key Players of Methylxanthines
Table 8. Key Players of Long-Acting Bronchodilators
Table 9. Key Players of Phosphodiesterase-4 Inhibitors
Table 10. Key Players of Others
Table 11. Global Chronic Obstructive Pulmonary Disorder Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Chronic Obstructive Pulmonary Disorder Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Chronic Obstructive Pulmonary Disorder Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2015-2020)
Table 15. Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Chronic Obstructive Pulmonary Disorder Market Growth Strategy
Table 21. Main Points Interviewed from Key Chronic Obstructive Pulmonary Disorder Players
Table 22. Global Chronic Obstructive Pulmonary Disorder Revenue by Players (2015-2020) (Million US$)
Table 23. Global Chronic Obstructive Pulmonary Disorder Market Share by Players (2015-2020)
Table 24. Global Top Chronic Obstructive Pulmonary Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disorder as of 2019)
Table 25. Global Chronic Obstructive Pulmonary Disorder by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Chronic Obstructive Pulmonary Disorder Product Solution and Service
Table 28. Date of Enter into Chronic Obstructive Pulmonary Disorder Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 31. Global Chronic Obstructive Pulmonary Disorder Market Size Share by Type (2015-2020)
Table 32. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type (2021-2026)
Table 33. Global Chronic Obstructive Pulmonary Disorder Market Size Share by Application (2015-2020)
Table 34. Global Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 35. Global Chronic Obstructive Pulmonary Disorder Market Size Share by Application (2021-2026)
Table 36. North America Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 38. North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 39. North America Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 40. North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 41. North America Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 42. Europe Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 44. Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 46. Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 48. China Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 49. China Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 50. China Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 51. China Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 52. China Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 53. China Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 54. Japan Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 56. Japan Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 58. Japan Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 62. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 64. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 66. India Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 67. India Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 68. India Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 69. India Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 70. India Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 71. India Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Chronic Obstructive Pulmonary Disorder Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Chronic Obstructive Pulmonary Disorder Market Share (2019-2020)
Table 74. Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Chronic Obstructive Pulmonary Disorder Market Share by Type (2015-2020)
Table 76. Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Chronic Obstructive Pulmonary Disorder Market Share by Application (2015-2020)
Table 78. GSK Company Details
Table 79. GSK Business Overview
Table 80. GSK Product
Table 81. GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 82. GSK Recent Development
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Product
Table 86. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 87. Pfizer Recent Development
Table 88. Merck Company Details
Table 89. Merck Business Overview
Table 90. Merck Product
Table 91. Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 92. Merck Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis Product
Table 96. Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 97. Novartis Recent Development
Table 98. AstraZeneca Company Details
Table 99. AstraZeneca Business Overview
Table 100. AstraZeneca Product
Table 101. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 102. AstraZeneca Recent Development
Table 103. Boehringer Ingelheim Company Details
Table 104. Boehringer Ingelheim Business Overview
Table 105. Boehringer Ingelheim Product
Table 106. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 107. Boehringer Ingelheim Recent Development
Table 108. Teva Pharmaceuticals Company Details
Table 109. Teva Pharmaceuticals Business Overview
Table 110. Teva Pharmaceuticals Product
Table 111. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 112. Teva Pharmaceuticals Recent Development
Table 113. Ario Pharma Business Overview
Table 114. Ario Pharma Product
Table 115. Ario Pharma Company Details
Table 116. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 117. Ario Pharma Recent Development
Table 118. Roche Company Details
Table 119. Roche Business Overview
Table 120. Roche Product
Table 121. Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 122. Roche Recent Development
Table 123. Ache Company Details
Table 124. Ache Business Overview
Table 125. Ache Product
Table 126. Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 127. Ache Recent Development
Table 128. Almirall Company Details
Table 129. Almirall Business Overview
Table 130. Almirall Product
Table 131. Almirall Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 132. Almirall Recent Development
Table 133. Aquinox Pharmaceuticals Company Details
Table 134. Aquinox Pharmaceuticals Business Overview
Table 135. Aquinox Pharmaceuticals Product
Table 136. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 137. Aquinox Pharmaceuticals Recent Development
Table 138. Asmacure Company Details
Table 139. Asmacure Business Overview
Table 140. Asmacure Product
Table 141. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 142. Asmacure Recent Development
Table 143. Astellas Pharma Company Details
Table 144. Astellas Pharma Business Overview
Table 145. Astellas Pharma Product
Table 146. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2015-2020) (Million US$)
Table 147. Astellas Pharma Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Obstructive Pulmonary Disorder Market Share by Type: 2020 VS 2026
Figure 2. Short-Acting Bronchodilators Features
Figure 3. Corticosteroids Features
Figure 4. Methylxanthines Features
Figure 5. Long-Acting Bronchodilators Features
Figure 6. Phosphodiesterase-4 Inhibitors Features
Figure 7. Others Features
Figure 8. Global Chronic Obstructive Pulmonary Disorder Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Chronic Obstructive Pulmonary Disorder Report Years Considered
Figure 13. Global Chronic Obstructive Pulmonary Disorder Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions: 2020 VS 2026
Figure 15. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Chronic Obstructive Pulmonary Disorder Market Share by Players in 2019
Figure 18. Global Top Chronic Obstructive Pulmonary Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disorder as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder Revenue in 2019
Figure 20. North America Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 29. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 31. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 33. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 35. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 37. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 39. Teva Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 41. Ario Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 43. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 45. Ache Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 47. Almirall Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 49. Aquinox Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 51. Asmacure Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 53. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2015-2020)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Keyplayers in Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2020-2026
GSKPfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma